A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 08 2020
Historique:
received: 31 10 2019
accepted: 09 07 2020
entrez: 10 8 2020
pubmed: 10 8 2020
medline: 10 9 2020
Statut: epublish

Résumé

Sporadic Creutzfeldt-Jakob disease (sCJD) presents as a rapidly progressive dementia which is usually fatal within six months. No clinical blood tests are available for diagnosis or disease monitoring. Here, we profile blood microRNA (miRNA) expression in sCJD. Sequencing of 57 sCJD patients, and healthy controls reveals differential expression of hsa-let-7i-5p, hsa-miR-16-5p, hsa-miR-93-5p and hsa-miR-106b-3p. Downregulation of hsa-let-7i-5p, hsa-miR-16-5p and hsa-miR-93-5p replicates in an independent cohort using quantitative PCR, with concomitant upregulation of four mRNA targets. Absence of correlation in cross-sectional analysis with clinical phenotypes parallels the lack of association between rate of decline in miRNA expression, and rate of disease progression in a longitudinal cohort of samples from 21 patients. Finally, the miRNA signature shows a high level of accuracy in discriminating sCJD from Alzheimer's disease. These findings highlight molecular alterations in the periphery in sCJD which provide information about differential diagnosis and improve mechanistic understanding of human prion diseases.

Identifiants

pubmed: 32769986
doi: 10.1038/s41467-020-17655-x
pii: 10.1038/s41467-020-17655-x
pmc: PMC7414116
doi:

Substances chimiques

Biomarkers 0
MicroRNAs 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3960

Subventions

Organisme : Medical Research Council
ID : MC_U123160657
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U123160651
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00024/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00024/9
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400713
Pays : United Kingdom

Références

Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci.24, 519–550 (2001).
pubmed: 11283320
Bolton, D. C., McKinley, M. P. & Prusiner, S. B. Identification of a protein that purifies with the scrapie prion. Science218, 1309–1311 (1982).
pubmed: 6815801
Terry, C. et al. Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. Open Biol. 6, https://doi.org/10.1098/rsob.160035 (2016).
Mead, S. et al. Clinical trial simulations based on genetic stratification and the natural history of a functional outcome measure in Creutzfeldt-Jakob disease. JAMA Neurol.73, 447–455 (2016).
pubmed: 26902324 pmcid: 5701731
Windl, O. et al. Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum. Genet.98, 259–264 (1996).
pubmed: 8707291
Parchi, P. et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann. Neurol.46, 224–233 (1999).
pubmed: 10443888
Glatzel, M., Abela, E., Maissen, M. & Aguzzi, A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med.349, 1812–1820 (2003).
pubmed: 14602879
Head, M. W. et al. Abnormal prion protein in the retina of the most commonly occurring subtype of sporadic Creutzfeldt-Jakob disease. Br. J. Ophthalmol.89, 1131–1133 (2005).
pubmed: 16113366 pmcid: 1772846
Orru, C. D. et al. Prion seeds distribute throughout the eyes of sporadic Creutzfeldt-Jakob disease patients. MBio9, https://doi.org/10.1128/mBio.02095-18 (2018).
Orru, C. D. et al. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci. Transl. Med. 9, https://doi.org/10.1126/scitranslmed.aam7785 (2017).
He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet.5, 522–531 (2004).
pubmed: 15211354
Rayner, K. J. & Hennessy, E. J. Extracellular communication via microRNA: lipid particles have a new message. J. Lipid Res.54, 1174–1181 (2013).
pubmed: 23505318 pmcid: 3622315
Correia, C. N. et al. Circulating microRNAs as potential biomarkers of infectious disease. Front. Immunol.8, 118 (2017).
pubmed: 28261201 pmcid: 5311051
Kai, K., Dittmar, R. L. & Sen, S. Secretory microRNAs as biomarkers of cancer. Semin. Cell Dev. Biol.78, 22–36 (2018).
pubmed: 29258963
Viswambharan, V., Thanseem, I., Vasu, M. M., Poovathinal, S. A. & Anitha, A. miRNAs as biomarkers of neurodegenerative disorders. Biomark. Med.11, 151–167 (2017).
pubmed: 28125293
Abe, M. & Bonini, N. M. MicroRNAs and neurodegeneration: role and impact. Trends Cell Biol.23, 30–36 (2013).
pubmed: 23026030
Hebert, S. S. & De Strooper, B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci.32, 199–206 (2009).
pubmed: 19268374
Liguori, M. et al. Dysregulation of microRNAs and target genes networks in peripheral blood of patients with sporadic. Amyotroph. Lateral Scler. Front. Mol. Neurosci.11, 288 (2018).
Tan, L., Yu, J. T. & Tan, L. Causes and consequences of microRNA dysregulation in neurodegenerative diseases. Mol. Neurobiol.51, 1249–1262 (2015).
pubmed: 24973986
Kanata, E. et al. MicroRNA alterations in the brain and body fluids of humans and animal prion disease models: current status and perspectives. Front. Aging Neurosci.10, 220 (2018).
pubmed: 30083102 pmcid: 6064744
Slota, J. A. et al. Identification of circulating microRNA signatures as potential biomarkers in the serum of elk infected with chronic wasting disease. Sci. Rep.9, 19705 (2019).
pubmed: 31873177 pmcid: 6928025
Choi, E. M. et al. Prion proteins in subpopulations of white blood cells from patients with sporadic Creutzfeldt-Jakob disease. Lab. Invest.89, 624–635 (2009).
pubmed: 19434060 pmcid: 2786774
Jung, M. et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin. Chem.56, 998–1006 (2010).
pubmed: 20378769
Giovanni, A. et al. E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. J. Biol. Chem.275, 11553–11560 (2000).
pubmed: 10766769
Hoglinger, G. U. et al. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson’s disease. Proc. Natl Acad. Sci. USA104, 3585–3590 (2007).
pubmed: 17360686
Ranganathan, S. & Bowser, R. Alterations in G(1) to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am. J. Pathol.162, 823–835 (2003).
pubmed: 12598317 pmcid: 1868100
Gupta, S. et al. Perk-dependent repression of miR-106b-25 cluster is required for ER stress-induced apoptosis. Cell Death Dis.3, e333 (2012).
pubmed: 22739985 pmcid: 3388242
Stefani, I. C., Wright, D., Polizzi, K. M. & Kontoravdi, C. The role of ER stress-induced apoptosis in neurodegeneration. Curr. Alzheimer Res.9, 373–387 (2012).
pubmed: 22299619
Dong, H. et al. Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer’s disease. Dis. Markers2015, 625659 (2015).
pubmed: 26078483 pmcid: 4452867
Balakrishnan, I. et al. Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells32, 662–673 (2014).
pubmed: 24038734 pmcid: 4127404
Boudreau, R. L. et al. Transcriptome-wide discovery of microRNA binding sites in human brain. Neuron81, 294–305 (2014).
pubmed: 24389009 pmcid: 4108341
Kishore, S. et al. A quantitative analysis of CLIP methods for identifying binding sites of RNA-binding proteins. Nat. Methods8, 559–564 (2011).
pubmed: 21572407
Lau, P. et al. Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol. Med.5, 1613–1634 (2013).
pubmed: 24014289 pmcid: 3799583
Sorensen, S. S., Nygaard, A. B. & Christensen, T. miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia - an exploratory study. Transl. Neurodegener.5, 6 (2016).
pubmed: 26981236 pmcid: 4791887
Bellingham, S. A., Coleman, B. M. & Hill, A. F. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res.40, 10937–10949 (2012).
pubmed: 22965126 pmcid: 3505968
Burak, K. et al. MicroRNA-16 targets mRNA involved in neurite extension and branching in hippocampal neurons during presymptomatic prion disease. Neurobiol. Dis.112, 1–13 (2018).
pubmed: 29277556
Majer, A. et al. Early mechanisms of pathobiology are revealed by transcriptional temporal dynamics in hippocampal CA1 neurons of prion infected mice. PLoS Pathog.8, e1003002 (2012).
pubmed: 23144617 pmcid: 3493483
Llorens, F. et al. Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis. PLoS Pathog.14, e1006802 (2018).
pubmed: 29357384 pmcid: 5794191
Hebert, S. S., Sergeant, N. & Buee, L. MicroRNAs and the regulation of tau. Metab. Int. J. Alzheimers Dis.2012, 406561 (2012).
Liu, W. et al. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol. Aging33, 522–534 (2012).
pubmed: 20619502
McKeever, P. M. et al. MicroRNA expression levels are altered in the cerebrospinal fluid of patients with young-onset Alzheimer’s disease. Mol. Neurobiol.55, 8826–8841 (2018).
pubmed: 29603092 pmcid: 6208843
Cheng, L. et al. Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol. Psychiatry20, 1188–1196 (2015).
pubmed: 25349172
Boese, A. S. et al. MicroRNA abundance is altered in synaptoneurosomes during prion disease. Mol. Cell Neurosci.71, 13–24 (2016).
pubmed: 26658803
Polymenidou, M. & Cleveland, D. W. The seeds of neurodegeneration: prion-like spreading in ALS. Cell147, 498–508 (2011).
pubmed: 22036560 pmcid: 3220614
Smethurst, P. et al. In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol. Dis.96, 236–247 (2016).
pubmed: 27590623 pmcid: 5113659
Smethurst, P., Sidle, K. C. & Hardy, J. Review: Prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathol. Appl. Neurobiol.41, 578–597 (2015).
pubmed: 25487060
Fuchs Wightman, F., Giono, L. E., Fededa, J. P. & de la Mata, M. Target RNAs Strike Back on MicroRNAs. Front. Genet.9, 435 (2018).
pubmed: 30333855 pmcid: 6175985
Ash, P. E., Vanderweyde, T. E., Youmans, K. L., Apicco, D. J. & Wolozin, B. Pathological stress granules in Alzheimer’s disease. Brain Res.1584, 52–58 (2014).
pubmed: 25108040 pmcid: 4256948
Vanderweyde, T. et al. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. J. Neurosci.32, 8270–8283 (2012).
pubmed: 22699908 pmcid: 3402380
Staffaroni, A. M. et al. Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol.76, 969–977 (2019).
pmcid: 6503575
Thompson, A. G. B. et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J. Neurol. Neurosurg. Psychiatry89, 955–961 (2018).
pubmed: 29487167 pmcid: 6109239
Blondal, T. et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods59, S1–S6 (2013).
pubmed: 23036329
Kirschner, M. B. et al. The impact of hemolysis on cell-free microRNA biomarkers. Front. Genet.4, 94 (2013).
pubmed: 23745127 pmcid: 3663194
Ludwig, N. et al. Machine learning to detect Alzheimer’s disease from circulating non-coding RNAs. Genomics Proteom. Bioinformatics17, 430–440 (2019).
Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat. Genet.45, 580–585 (2013).
Thompson, A. G. et al. The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain136, 1116–1127 (2013).
pubmed: 23550114
Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol.13, 614–629 (2014).
pubmed: 24849862
Karagkouni, D. et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res.46, D239–D245 (2018).
pubmed: 29156006
Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics14, 128 (2013).
pubmed: 23586463 pmcid: 3637064
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res.44, W90–W97 (2016).
pubmed: 4987924 pmcid: 4987924

Auteurs

Penny J Norsworthy (PJ)

MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Andrew G B Thompson (AGB)

National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Tze H Mok (TH)

National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Fernando Guntoro (F)

MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Luke C Dabin (LC)

MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Akin Nihat (A)

National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Ross W Paterson (RW)

Dementia Research Centre, UCL Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.

Jonathan M Schott (JM)

Dementia Research Centre, UCL Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.

John Collinge (J)

MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.
National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Simon Mead (S)

MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK. s.mead@prion.ucl.ac.uk.
National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK. s.mead@prion.ucl.ac.uk.

Emmanuelle A Viré (EA)

MRC Prion Unit at UCL, UCL Institute of Prion Diseases, Courtauld Building, 33 Cleveland Street, London, W1W 7FF, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH